Archive for March, 2021

$PCSA Releases FY 2020 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial numbers for the year ending Dec. 31, 2020; the company also reported a corporate update. High on the list of noteworthy achievements for the year 2020 was the selection of five U.S. clinical sites for the enrollment of patients for the company’s upcoming phase 2B trial; exclusive licensing agreements with Elion Oncology Inc. and Yuhan Corporation; the appointment of new board and executive team members; and the closing of an underwritten public offering that resulted in $17.1 million. The update also noted that the company anticipated seeing the first patients in its phase 1B clinical study and its phase 2 study dosed in the first half of 2021. Processa Pharmaceuticals held a March 25 conference call reviewing the report; a reply of that call can be obtained by dialing toll-free 877-481-4010 for domestic callers and 919-882-2331 for international callers; the passcode for either call is 40452. “2020 was a transformational year for our company,” said Processa CEO and chair Dr. David Young in the press release. “We in-licensed three exciting programs with potential markets exceeding $1 billion for each drug, improved our balance sheet, strengthened our management team and board, uplisted to Nasdaq, and prepared the foundation for successful execution for our three clinical-stage programs. I am delighted to report that we anticipate the first patients to be dosed with PCS6422 and PCS499 in the second quarter of 2021 with interim data for PCS6422 near the end of Q3 and for PCS499 in the first quarter of 2022.”

To view the full press release, visit: https://ibn.fm/KJwtO

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. PCSA’s active clinical pipeline programs include PCS6422 (“PCS6422”) (metastatic colorectal cancer and breast cancer), PCS499 (“PCS499”) (ulcerative Necrobiosis Lipoidica) and PCS12852 (“PCS12852”) (gastroparesis). The markets of each indication are in excess of $1 billion each. The members of the Processa development team have been involved with more than 30 FDA drug approvals, including drug products targeted to orphan disease conditions, and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $PCSA Releases FY 2020 Financial, Corporate Report

$MEDS Releases Quarter, FY 2020 Financial Report

Trxade Group (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, has reported its financial results for fourth quarter and fiscal year for the period ended Dec. 31, 2020. The report also included key operational highlights. Financial numbers noted that the company’s revenues for the quarter increased 17.1% to $2 million, compared to revenue of $1.7 million in the same quarter last year; gross profit for Q4 decreased, primarily because of higher costs associated with Trxade Prime transactions and a write down of inventory. Revenues for the full year increased 130.3% to $17.1 million, compared to $7.4 million in the previous year, with full-year 2020 gross profits reaching $5.7 million, an increase of 17.2% over the previous year. The company continues to expand the Trxade drug procurement marketplace nationwide; Q4 saw an additional 328 new registered members, bringing the total registered members to more than 11,800. In addition, Trxade’s telehealth subsidiary Bonum Health agreed to provide affordable telemedicine services to the patients of approximately 100 Kinney Drug retail pharmacies in New York and Vermont, as well as more than two million Rx discount card members of Kinney’s sister company, ProAct Inc. “2020 was a milestone year for our company as we continued to innovate, grow and expand,” said SRAX chair and CEO Suren Ajjarapu in the press release. “Despite the challenges of a global pandemic, we increased revenues by 130% for the year, a testament to our team’s continued innovation and development of our breakthrough digital healthcare services IT platform. As we continue to scale exciting new affiliated services, such as our telehealth platform or our recently announced digital health passport initiative, we anticipate continued top line growth in the coming year.”

To view the full press release, visit http://ibn.fm/0HCoT

About Trxade Group Inc.

Trxade Group is a health-services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug-procurement marketplace serving a total of 11,800-plus members nationwide and fostering price transparency as well as the Bonum Health brand, offering patient centric telehealth services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $MEDS Releases Quarter, FY 2020 Financial Report

$GNPX Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (“NSCLC”), will be featured in two presentations at the upcoming annual meeting of the American Association for Cancer Research (“AACR 21”). The event is slated to take place virtually from April 9-14, 2021. “We look forward to the presentation of these data that highlight the potential of TUSC2 immunogene therapy to enhance chemo-immune combination treatments and overcome resistance to osimertinib in lung cancer, to an audience of the world’s leading cancer researchers,” said Rodney Varner, president and chief executive officer of Genprex. “As lung cancer is the leading cause of cancer deaths worldwide, we remain keenly focused on initiating our Acclaim-1 and Acclaim-2 clinical trials to evaluate REQORSA, our proprietary TUSC2 immunogene therapy, in non-small cell lung cancer.”

To view the full press release, visit: https://ibn.fm/ajAYO

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $GNPX Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21

$MOTNF More Hydrogen-Powered Cars Are Coming; Can They Be Fueled?

NetworkNewsWire Editorial Coverage: Cars and trucks powered by hydrogen, the most abundant resource in the universe, are on the road now with more planned and in production. Hydrogen power may well be the solution to truly weaning from fossil fuels, turning the tide on CO2 emissions and ushering in a new era of emission-free transportation — but only if vehicles running on the power can find fuel. Even with major automakers rolling out new hydrogen vehicles and a wealth of hydrogen in the universe, there’s a serious shortage of hydrogen fueling stations. With less than 100 public hydrogen stations in the USA, hydrogen fueling stations are the missing infrastructure critical to propel and sustain hydrogen vehicle growth. Using patented next-generation technology, Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) (Profileintends to rectify the paucity of hydrogen fueling stations and become a powerful factor as ever more hydrogen vehicles take to the road. Clean Power Capital owns 94.5% of PowerTap Hydrogen Fueling Corp., which builds, installs and supports low-cost, onsite hydrogen fueling and dispensing units. PowerTap’s 2nd Generation technology has 14 installations already in place in the USA (which are not owned by PowerTap Hydrogen Fueling Corp.). The company inked a deal in January with the Andretti Group to install PowerTap’s 3rd Generation modular hydrogen fueling stations starting in California this year. This is just one of many partnerships planned with major fueling networks to install hydrogen fuel technology at existing locations across the nation, and the rollout can’t come too soon. Toyota Motor Corporation (NYSE: TM) recently revealed it has developed and plans on selling a product this year that packages a fuel cell system into a compact module. Integrating the main components of a fuel cell makes it easily adaptable for rapid development and manufacture of a variety fuel cell products. Credited for creating the first commercially market for hydrogen fuel cell technology, Plug Power Inc. (NASDAQ: PLUG) is building the hydrogen economy as a leading provider of comprehensive hydrogen fuel-cell turnkey solutions. ITM Power Plc (OTC: ITMPF) manufactures integrated hydrogen energy solutions for grid balancing, energy storage and the production of renewable hydrogen for transport, renewable heat, and chemicals. And Nel ASA (OTC: NLLSF) is a global hydrogen company dedicated to delivering optimal solutions to produce, store and distribute hydrogen from renewable energy.

  • Shift to clean, safe, abundant, sustainable and cost-effective hydrogen power is underway.
  • Hydrogen-powered vehicles already on the road with more passenger cars and trucks as well as long-haul trucks planned.
  • Clean Power subsidiary PowerTap now owns 14 hydrogen fueling stations; intends to build largest hydrogen fueling station network in North America.
  • PowerTap’s patented technology, unique business model give it competitive advantages.

Why Hydrogen?

Produced from diverse domestic resources, hydrogen is the most abundant chemical substance in the universe and holds strong promise for growth in both the transportation and energy sectors. The abundance of hydrogen and the relative simplicity of use are propelling a surge of new hydrogen vehicles, which use fuel cells to create electric power.

Electric power is first generated in a fuel cell when hydrogen and air are pushed into opposite sides of a fuel cell and the two chemically react to produce electricity, water vapor and small amounts of heat. Electricity then flows from the fuel cell to power the vehicle’s electric motor. Hydrogen fuel cells are much cleaner and more efficient than traditional internal combustion engines and fossil fuel power plants.

Most power plants achieve about 35% efficiency, and internal combustion engines operate around 25% efficiency. Comparatively, stationary fuel cells when used in a combined heat and power system, can reach efficiency levels of greater than 80%. Amazingly, a fuel cell coupled with an electric motor is two to three times more efficient than an internal combustion engine running on gasoline. When hydrogen is used to power a fuel cell, the only byproducts are water and heat – zero pollutants or greenhouse gases are produced.

Powerful Combo

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) and its subsidiary PowerTap is leveraging tens of millions of dollars of historical invested capital in the PowerTap technology, a portfolio of patented technologies and partnerships with major fueling networks to meet coming demand as hydrogen vehicles hit the highways. Recognizing the value of the technology and the massive opportunity, Clean Power took a 94.5% equity stake in PowerTap in the last year. PowerTap’s small-footprint SMR technology produces blue hydrogen onsite at existing filling stations as opposed to typical off-site production then delivers to a filling station. Most hydrogen fueling stations buy offsite hydrogen and store hydrogen at the station level  at much higher costs, and Clean Power is convinced that PowerTap’s unique model is exponentially more scalable and cost effective.

PowerTap shares revenues with individual fueling stations as well as partner major fueling networks in return for hosting PowerTap Hydrogen fueling stations at their locations. By partnering with and incentivizing major fueling networks to install hydrogen fuel technology at existing locations, the unique PowerTap business model simplifies and rapidly accelerates deployment.

Clean Power’s investment allowed PowerTap to ramp up efforts to expand the hydrogen fueling station network in stages, starting with engineering, design and further development of PowerTap’s third-generation product, as well as licensing & permitting and site preparation. The design of the PowerTap Gen3 hydrogen fueling units station is less than half the size of the closest competitor, easy to relocate if needed and able to quickly adopt other new hydrogen production technologies since PowerTap can upgrade its technology onsite.

Clean Power’s investment is already producing results. In addition, the company just announced an update on the third-generation PowerTap (Gen3) hydrogen fueling units, noting in part that “PowerTap Gen3’s advanced CCS [CO2 capture system] uses a unique process incorporating a chemical reaction that consumes the CO2 and produces excess hydrogen. This excess hydrogen is converted into clean renewable electricity via a universal fuel cell and the produced electricity can be fed back into the local electric grid or used to create a renewable microgrid for local power distribution via a universal fuel cell to power the gas/truck stop facility at which the PowerTap unit is located.”

Majors Making Moves

Clean Power and PowerTap are quickly prepping for a tsunami of expected demand illustrated by Toyota’s new universal fuel cell, which makes it much easier for hydrogen vehicle OEMs to launch new hydrogen-powered cars, trucks, boats, motorbikes and virtually anything else previously powered by fossil fuels. In addition to its effort to popularize fuel cell-powered EVs, Toyota intends to continue to strengthen its initiatives as a fuel cell system supplier to promote hydrogen utilization. Toyota launched a 2021 hydrogen powered Mirai and is nearing production of next-generation fuel cell electric technology for zero-emissions heavy duty trucks using the same fuel cell system.

Toyota isn’t alone — Hyundai, Honda, and BMW either make or plan hydrogen-powered cars, and Hyundai, Nikola Motors, Volvo and Daimler have announced plans to manufacture trucks. PowerTap intends to fuel these vehicles and all those that follow.

This is just the beginning of what will likely be strong consumer demand, especially from the trucking industry where the economics have potential to impact bottom lines. Diesel long-haul trucks have an 812-mile range, a 15- to 30-minute fueling time and cost 33.44 cents per mile to operate; the same truck with an electric battery has a 400-mile range, takes up to eight hours to charge and costs 37.5 cents per mile. By contrast, a Class 8 hydrogen-powered truck has a 900-mile range, takes 15 to 30 minutes to refuel, and costs only 15 cents per mile to operate. Consider that U.S. truckers drive an estimated 140 billion miles every year, and it’s easy to see why hydrogen-powered heavy duty trucks are coming to market.

Market timing couldn’t be better for PowerTap’s Gen3 modular blue hydrogen production and dispensing unit. As ever more hydrogen vehicles come to market, the opportunities for PowerTap and Clean Power could grow exponentially.

“PowerTap’s patented, onsite blue hydrogen-generating fuel station technology is the right solution for today’s lack of hydrogen fueling infrastructure,” said PowerTap COO Kelley Owen. “PowerTap plans to roll out hydrogen fueling stations to meet the USA’s public hydrogen fueling station increased demand. Our new modular design will allow us to deploy our stations rapidly starting in 2021.”

And this is just the start. With its patented state-of-the-art technology and access to capital in place through Clean Power, PowerTap fully intends to build the largest, most functional and profitable hydrogen fueling station network across all of North America.

Hydrogen Apostles

Toyota Motor Corporation (NYSE: TM) engages in the manufacture and sale of motor vehicles and parts. It operates through automotive financial services and other segments. The company recently revealed it has developed and plans to sell a product that packages a fuel cell system into a compact module. Integrating the main components of a fuel cell will make it easily adaptable for rapid development.

Plug Power Inc. (NASDAQ: PLUG) is credited for creating the first commercially market for hydrogen fuel cell technology and is building the hydrogen economy as a leading provider of comprehensive hydrogen fuel cell turnkey solutions. The company’s innovative technology powers electric motors with hydrogen fuel cells amid an ongoing paradigm shift in the power, energy and transportation industries to address climate change and energy security, while providing efficiency gains and meeting sustainability goals.

ITM Power Plc (OTC: ITMPF) manufactures integrated hydrogen energy solutions for grid balancing, energy storage and the production of renewable hydrogen for transport, renewable heat and chemicals. The company is a recognized expert in hydrogen technologies with the overarching principle to take excess energy from the power network, convert it into hydrogen and use it in one of three broad market areas: mobility, power-to-X and industry.

Nel ASA (OTC: NLLSF) is a Norwegian-based hydrogen company dedicated to delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. The company’s hydrogen solutions cover the entire value chain from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen and providing all fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles  — without emissions.

The world is fast moving away from fossil fuels, and hydrogen looks to play an important part. Clean and abundant, hydrogen power is gaining favor, and as the crescendo builds, insightful investors take notice.

For more information on Clean Power Capital Corp., please visit Clean Power Capital Corp.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $MOTNF More Hydrogen-Powered Cars Are Coming; Can They Be Fueled?

$UEC Featured in Bell2Bell Podcast

Uranium Energy (NYSE American: UEC), a Corpus Christi, Texas-based uranium mining and exploration company, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Uranium Energy’s CEO and President, Amir Adnani, joined the latest episode to discuss the company’s recent news and milestones, which include strengthening of its balance sheet that totals close to $95 million in cash and equity holdings, including approximately $61 million in cash. Adnani also discussed the company’s establishment of a physical uranium holding initiative. “This has really both resonated with the market and, in my opinion, is just sound business for us,” Adnani said in the interview. “We are, as a company, focused entirely on developing low-cost in-situ recovery uranium projects in the U.S., but we’re looking at a spot uranium price that, after a decade of being in a bear market, is starting to recover. We’re seeing great positive signs, but the spot uranium price – in and around $30 per pound – is still lower than the prevailing mining cost for most industry players anywhere in the world. We saw a unique opportunity to come out and acquire physical uranium that can be warehoused right here in the U.S. and will give the company a balance sheet asset that, as the uranium price goes up, can appreciate.”

To view the full press release, visit https://ibn.fm/tFkBN

About Uranium Energy Corp.

Uranium Energy is a U.S.-based uranium mining and exploration company. As a leading pure-play American uranium company, UEC is advancing the next generation of low-cost and environmentally friendly in-situ recovery (“ISR”) mining uranium projects. In South Texas, the company’s hub-and-spoke operations are anchored by UEC’s fully-licensed Hobson Processing Facility, which is central to its Palangana, Burke Hollow, Goliad and other ISR pipeline projects. In Wyoming, UEC controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the company’s diversified holdings provide exposure to a unique portfolio of uranium related assets, including: 1) major equity stake in the only royalty company in the sector, Uranium Royalty Corp; 2) physical uranium warehoused in the U.S.; and 3) a pipeline of resource-stage uranium projects in Arizona, Colorado, New Mexico and Paraguay. In Paraguay, the company owns one of the largest and highest-grade ferro-titanium deposits in the world. The company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining. For more information about the company, visit www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at http://ibn.fm/UEC

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $UEC Featured in Bell2Bell Podcast

$SRAX Releases Q4 Numbers, Operational Highlights

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (”SaaS”) platform, has reported its fourth-quarter 2020 numbers; the report also noted company highlights for the quarter and full year. According to the announcement, the company saw Q4 revenue of $4.5 million, an increase of 316% year over year and a 74% increase quarter over quarter. The company’s full-year revenue guidance increase from $17–$18 million to $23–$25 million. SRAX noted that its Sequire SaaS had seen eight quarters of growth, with bookings of $4.8 million for the fourth quarter and $10 million for Q1; 183 public companies or partners have subscribed to Sequire, which is almost double from the company’s Q3 report. “We are making great progress with our platform and we are seeing continued adoption of the products that we are building for issuers. We had another record quarter of bookings for Sequire,” said SRAX founder and CEO Christopher Miglino in the press release. “In the first quarter of 2021 we have closed over $10 million in contracts. This momentum is not slowing down and we are growing the business to accommodate this demand. Our team did an amazing job in delivering a number of cutting-edge technological improvements to the platform and they have laid the foundation for some amazing enhancements that we will bring to market throughout the rest of this year. I could not be more proud of the hard work and dedication that the team has demonstrated as our sales continue to skyrocket.”

To view the full press release, visit http://ibn.fm/qHotW

About SRAX

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $SRAX Releases Q4 Numbers, Operational Highlights

$POAI Leverages Multi-Omic Approach to New Drug Discovery

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a much greater ability for success. The company is a leader in this area where few comprehensive, multi-omic datasets exist, especially in cancer, and such data is difficult to quickly access, as well as costly and time-consuming to collect. “The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer,” reads a recent article discussing the company’s positioning. “The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes.”

To view the full article, visit: https://ibn.fm/1bKIk

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $POAI Leverages Multi-Omic Approach to New Drug Discovery

$MWK CEO Featured on DealMaker Show

Mohawk Group (NASDAQ: MWK) co-founder and CEO Yaniv Sarig was featured on a recent episode of The DealMaker show. The Dealmaker Show is a fast-paced, high-energy forum hosted by best-selling author Oren Klaff. During the interview, Sarig talked about the Mohawk Group business model and as well as discussing the company’s proprietary AIMEE(R) (“AIMEE”) platform, which is designed to automate the development and launch of best-selling consumer products. Sarig also shared how the company is working to leverage and strengthen its foothold in the ecommerce space. “What we’ve done with Mohawk is we’ve built a hybrid of a technology company and a consumer company,” said Mohawk Group co-founder and CEO Yaniv Sarig during the interview. “Our business is to sell consumer products to the end consumers. We actually have built, on our own, five different brands; we recently acquired our number seven brand, so we manage 12 different consumer brands that we own. . . . Instead of doing everything by hand, instead of having to constantly manage all the forecasting and all the media buying and figuring out the next product we need to make. . . . We went and built a very, very powerful technology platform that allows us to just build consumer product brands and products in a more efficient way. In a nutshell, what that platform does is it gathers a lot of data on what consumers want and tells us what products to make. It automates all the day-to-day management of those products.”

To listen to the full interview, visit https://ibn.fm/VWqwK

To view the full press release, visit https://ibn.fm/pzEBR

About Mohawk Group Holdings Inc.

Mohawk Group is a rapidly growing technology-enabled consumer products company that uses machine learning, natural language processing, and data analytics to design, develop, market and sell products. Mohawk predominantly operates through online retail channels such as Amazon and Walmart. Mohawk has twelve owned and operated brands and sells products in multiple categories, including home and kitchen appliances, kitchenware, environmental appliances (i.e., dehumidifiers and air conditioners), beauty-related products and, to a lesser extent, consumer electronics. Mohawk was founded on the premise that if a company selling consumer packaged goods was founded today, it would apply artificial intelligence and machine learning, the synthesis of massive quantities of data and the use of social proof to validate high caliber product offerings as opposed to over-reliance on brand value and other traditional marketing tactics. For more information about this company, please visit www.MohawkGP.com.

NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at http://ibn.fm/MWK

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $MWK CEO Featured on DealMaker Show

$CLXPF Appoints New Management Positions, Focused on Development and Clinical Operations

Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former SVP of business development John Kanakis will become chief business officer. The changes are effective immediately. An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone has extensive experience with quality assurance, regulatory affairs, product development, compliance and commercial operations. A well-known leader in the field of psychedelic research, Belser has served as an investigator on clinical trials of psilocybin and MDMA to treat depression, anxiety, substance use, obsessive-compulsive disorder (“OCD”), post-traumatic stress disorder (“PTSD”), and end-of-life distress at New York University and Yale University. “We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental healthcare through therapeutic development programs and innovative drug delivery systems,” said Cybin CEO Doug Drysdale in the press release. “These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron bring deep clinical, commercial and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets. Paul and John’s extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the company’s subsequent emergence as a leader within the psychedelics space. Their deep commitment to Cybin’s mission will continue as they assume these new roles and will allow them to further accelerate business development and investor awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level.”

To view the full press release, visit https://ibn.fm/eoj5u

About Cybin Inc.

Cybin Corp. (NEO: CBYN; OTC: CLXPF) is a leading biotech company focused on progressing psychedelic therapeutics. Cybin is on a mission to revolutionize mental healthcare. Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $CLXPF Appoints New Management Positions, Focused on Development and Clinical Operations

$AZRX Research Finds That Covid-19 Infection Increases Chance of Stroke Among Patients

Research conducted recently has discovered that individuals who are hospitalized with coronavirus infections have an increased risk of stroke in comparison with individuals who have similar infectious illnesses such as sepsis and influenza from previous studies.

The study found that patients who suffered from ischemic stroke were more likely to suffer from atrial fibrillations, type 2 diabetes, and high blood pressure, as well as come from the Black race, be male and be older. This was in comparison with other coronavirus patients. These findings were presented at this year’s American Stroke Association conference.

For their evaluation, the researchers analyzed data obtained from the COVID-19 CVD registry from the American Heart Association to explore the risk of stroke in patients who had been hospitalized for coronavirus infections, their demographics characteristics and medical histories. The data that was used in this study was gathered from more than 20,000 individuals who had been hospitalized with coronavirus last year across the United States from January to November.

University of Washington cardiology fellow Saate Shakil, who was also the lead author of the study, stated that the findings suggested that the coronavirus may increase the risk of stroke. The researchers found that during hospitalization, 281 people in the registry suffered a stroke, which had been confirmed via diagnostic imaging. Of this group, 7 individuals experienced a transient ischemic attack, 127 patients experienced unspecified types of stroke or bleeding stroke, and 148 individuals experienced an ischemic stroke.

The researchers’ investigation also led to the following discoveries:

  • As compared to deaths of patients who had not suffered strokes, in-hospital deaths were twice as high among stroke patients.
  • Patients who had suffered strokes spent more than three weeks hospitalized while those who did not suffer strokes spent a little more than a week hospitalized.
  • Approximately 9% of patients who had no strokes suffered from atrial fibrillation while 18% of patients who suffered ischemic strokes had atrial fibrillation.
  • While only 58% of patients without stroke suffered from high blood pressure, 80% of ischemic stroke patients also suffered from high blood pressure.
  • The researchers found that nearly a third of patients who did not have strokes had diabetes while 44% of ischemic stroke patients had type 2 diabetes.

Additionally, the researchers discovered that individuals who suffered any type of stroke were more likely to be older, with the average age being 65 and more likely to be males. The researchers also found that the risk of stroke varied by race, with Black patients making up 27% of the patients in the Cardiovascular Disease Registry pool.

Shakil explained that the team’s research suggested that African Americans had an increased risk of ischemic stroke after being infected with the coronavirus and noted that it was important that the coronavirus spread be contained through widespread distribution of vaccines and public health interventions.

COVID-19 and stroke aren’t the only health challenges the world is grappling with. Other conditions, such as chronic pancreatitis and cystic fibrosis, are also of concern. To find a remedy, AzurRx BioPharma Inc. (NASDAQ: AZRX) is conducting clinical trials of its drug candidate MS1819; topline data from these studies is expected this year.

NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $AZRX Research Finds That Covid-19 Infection Increases Chance of Stroke Among Patients

$VVOS Unveils New MyoCorrect Orofacial Myofunctional Therapy Service

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new service will provide increased revenue through With this new training, Vivos expects to see additional revenue through increased cases and fees. The company expects its MyoCorrect service will become an effective treatment of OSA, thereby giving Vivos an additional competitive advantage in the OSA treatment marketplace. “The launch of this new service is an important step for Vivos as we continue to offer what we believe are the best therapeutic options available for patients who suffer from sleep disordered breathing and the most prevalent forms of obstructive sleep apnea,” said Vivos chair and VEO Kirk Huntsman in the press release. “We believe we will be able to leverage our current infrastructure and growing dentist network for rapid deployment and adoption of the MyoCorrect OMT therapy. As Vivos-trained dentists come to experience the ways in which OMT can enhance their Vivos System case outcomes, we expect the adoption rate of MyoCorrect as an integral part of the Vivos System to rise. As that happens, the revenue contributions of MyoCorrect to Vivos in the form of increased Vivos System sales as well as fees charged for the OMT service could be significant.”

To view the full press release, visit: https://ibn.fm/i39O8

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in more than 18,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $VVOS Unveils New MyoCorrect Orofacial Myofunctional Therapy Service

$AMPG Is ‘One to Watch’

March 30, 2021

AmpliTech Group Inc. (NASDAQ: AMPG) Is ‘One to Watch’

  • The AmpliTech management team is led by Founder, President, CEO, and CTO Fawad Maqbool, who has been in the microwave industry for over 30 years
  • AmpliTech’s current catalog of devices is substantial, and it is always growing and adapting to include new technology
  • Currently, the company’s target markets include 5G/6G infrastructures, AR/VR, Cyber Security, Military/Defense, SATCOM, Autonomous Self-Driving Vehicles, and more
  • Current AmpliTech product offerings support a frequency range of 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz
  • The global microwave devices market was valued at $7.44 billion in 2019 and is expected to reach $9 billion by 2025, growing at a CAGR of 3.23%

AmpliTech Group (NASDAQ: AMPG, AMPGW) designs, develops and manufactures custom radio frequency (“RF”) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:

Amplifiers

Passive Components

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

  • Timely technical assistance
  • Little or no learning curve
  • Less long-term costs associated with full-time employees with benefits and salaries
  • Availability when necessary
  • Customer support with schedules, project management and on the job training
  • Access to technology
  • Partnering for manufacturing and/or complete turn-key product solution
  • Personal guidance from concept to development
  • Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://ibn.fm/4K2zG). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://ibn.fm/HOxeY). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

  • High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
  • 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
  • IoT (Internet of Things)
  • Cloud Farms, Big Data and MEC architecture
  • Quantum Supercomputers/Quantum Research
  • Deep Space Astronomy
  • Autonomous Self-Driving Vehicles
  • Telemedicine, AR/VR (Augmented and Virtual Reality)
  • Drones, UAVs (Unmanned Aerial Vehicles)
  • Cyber-security
  • Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (“CPA”) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

  1. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

For more information, visit the company’s website at www.AmpliTechInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, March 30th, 2021 Uncategorized Comments Off on $AMPG Is ‘One to Watch’

$CANSF Releases Q4 and FY 2020 Financial, Operational Report

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has announced its fourth-quarter and full-year numbers for the period ended Dec. 31, 2020. In the report, Willow noted that it had filed a short form base shelf prospectus that allowed the company to make offerings of securities of up to an aggregate of $50 million. The company also completed an overnight marketed public offering for gross proceeds of $11.5 million, which was upsized by $2.0 million and included the exercise of a 15% overallotment. In addition, Willow inked a deal with a leading ingredient manufacturing firm to produce commercial quantities of its ultra-pure cannabigerol (“CBG”) and began shipping commercial samples of its CBG to prospective customers. Willow ended the year with approximately $15.9 million of cash on hand. “We are very pleased with all of our achievements made in 2020 as a company and how they have set us up for a successful 2021,” said Will’s president and CEO Trevor Peters in the press release. “Looking back on the year we shortened our timelines to commercialization, moved beyond proof of concept with multiple pilot production runs, provided samples of our first cannabinoid to prospective customers, strengthened our balance sheet, and identified a partner and assets to commercialize our first cannabinoid. Ultra-pure, sustainably made, biosynthesized cannabinoids are the future of manufacturing consumer products with cannabinoids as a core ingredient. Commercializing our first cannabinoid this year will not only be a significant milestone for Willow, it will be significant for our industry.”

To view the full press release, visit: https://cnw.fm/aHo4V

About Willow Biosciences Inc.

Willow is a Canadian biotechnology company based in Vancouver, British Columbia, that produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is on the production of cannabinoids for the treatment for pain, anxiety, obesity, and brain disorders among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information about the company, visit www.WillowBio.com.

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://cnw.fm/WLLW

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Wednesday, March 24th, 2021 Uncategorized Comments Off on $CANSF Releases Q4 and FY 2020 Financial, Operational Report

$SYTA Announces Strategic Acquisition of ClearRF, LLC

Acquisition immediately synergistic to Siyata’s growing North American cellular booster business with additional expansion to U.S. manufacturing, providing potential critical access to U.S. military and defense contracts

VANCOUVER, British Columbia, March 24, 2021 — Siyata Mobile Inc. ( Nasdaq: SYTA, SYTAW (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular booster systems, has entered into a definitive share purchase agreement to acquire all the issued and outstanding shares of ClearRF, LLC (ClearRF), for a total purchase price of US$700,000 with a combination of cash and shares. The closing is expected to take place on or before March 31, 2021, and is subject to customary closing conditions.

Headquartered in Spokane, Wash., ClearRF produces M2M (machine-to-machine) cellular amplifiers for commercial and industrial M2M applications. ClearRF enables companies to deploy telemetry systems, remotely monitor and control their M2M applications in real-time and its products combine world-class innovation and industry experience and are designed and manufactured in the U.S.

ClearRF offers patented direct connect cellular amplifiers designed for M2M and “internet-of-things” (IoT) applications, specifically for fixed and mobile M2M applications to connect directly to any cellular router, modem, embedded module or alarm. ClearRF amplifiers provide a consistent, strong cellular signal in low or intermittent signal-challenged environments.

Key Benefits to Siyata:

  • Strategic acquisition to be immediately accretive to net income.
  • ClearRF’s patented RF Passive Bypass technology enables tethered devices to communicate through the amplifier network, even if the amplifier loses power, or when the signal is not required, a key differentiator amongst competitors, in particular for mission-critical applications and first responder vehicles that require constant clear cellular coverage and connectivity.
  • ClearRF’s patented Auto Gain & Oscillation Control detects the level of incoming signal strength and self-adjusts output power to ensure maximum signal strength. This feature is vital for telematics (mobile) M2M applications because the amplifier will be in constant motion and will require periodic self-adjustment based on changing incoming signal environment.
  • ClearRF’s devices are manufactured in the U.S. by Servatron Inc., a turnkey provider of custom, contract manufacturing services. Servatron is an ITAR Registered (International Traffic in Arms Regulations) facility and AS9100D Certified (a quality management system for Aviation, Space and Defense organizations).
  • Siyata will work with Servatron to develop next generation cellular amplifiers for military, government and first responders that require “Made in America” products.

“ClearRF’s products and technology are highly synergistic with Siyata’s rapidly growing cellular booster business and we believe it will enable us to accelerate the penetration of our M2M boosters and our flagship UV-350 in-vehicle IoT communication device, into the large scale in-vehicle modem market and provides us with access to new verticals and a key U.S. manufacturing partner,” said Marc Seelenfreund, CEO of Siyata Mobile. “ClearRF’s U.S. military certified manufacturing partner, Servatron, will also allow Siyata to enter the large-scale U.S. military and government markets that have special budgets for ‘Made in America’ products.”

“We are very excited to be joining forces with an industry disruptor and share the same commitment toward growth through innovation,” said Tod Byers, CEO of ClearRF. “With our combined capabilities, complementary technologies and expanded channels, we expect to accelerate growth within each of our core markets and disrupt the large and growing M2M industry.”

About Siyata Mobile

Siyata Mobile Inc. is a Business-to-Business (B2B) global vendor of next generation PoC devices and cellular booster systems. Its portfolio of in-vehicle and rugged smartphones enables first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to improve communication, increase situational awareness, and save lives.

Its portfolio of enterprise cellular booster systems enables first responders and enterprise workers to amplify its cellular signal in remote areas, inside structural buildings where signals are weak, and within vehicles for maximum cellular signal strength possible.

Siyata’s common shares trade on the Nasdaq under the symbol “SYTA” and its warrants under the symbol “SYTAW”.

Visit siyatamobile.com and unidencellular.com/ to learn more.

Investor Relations (Canada):
Kin Communications
1-866-684-6730
SYTA@kincommunications.com

Investor Relations (United States)
CORE IR
516-222-2560
SYTA@coreir.com

Sales Department:
Glenn Kennedy, VP International Sales
Siyata Mobile Inc.
416-892-1823
glenn_kennedy@siyatamobile.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Siyata is using forward-looking statements in this press release when it discusses its belief that the acquisition of ClearRF will be immediately accretive to net income, that ClearRF’s products and technology are highly synergistic with its cellular booster business and its belief that the acquisition will enable it to accelerate the penetration of its M2M boosters and its UV-350 in-vehicle IoT communication device, into the large scale in-vehicle modem market and provide it with access to new verticals and a key U.S. manufacturing partner, and that it intends to work with Servatron to develop cellular amplifiers for military, government and first responders that require “Made in America” products and that ClearRF’s U.S. military certified manufacturing partner will also allow it to enter the large-scale U.S. military and government markets that have special budgets for ‘Made in America’ products Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

Wednesday, March 24th, 2021 Uncategorized Comments Off on $SYTA Announces Strategic Acquisition of ClearRF, LLC

$SGLB Reports Fourth Quarter and Full Year 2020 Financial Results

2020 Global Agreements with 3D Printer OEMs, First Quarter Contracts and Increased Market Activity Signal Validation & Increased Adoption of PrintRite3D IPQA Solution

Management to Host Conference Call Today at 4:30 p.m. ET

SANTA FE, NM / March 24, 2021 / Sigma Labs, Inc. (NASDAQ:SGLB) (“Sigma Labs” or the “Company”), a leading developer of quality assurance software for the commercial 3D metal printing industry, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2020.

Key Fourth Quarter and Subsequent Operational Highlights

As previously announced:

  • Awarded contract from Lockheed Martin Space Additive Design & Manufacturing Center for an initial system of its PrintRite3D in-process quality assurance solution.
  • Closed a $5.1 million public offering of 1.7 million shares of common stock at a public offering price of $3.00, including the full exercise of the underwriter’s over-allotment option.
  • Announced worldwide cooperation agreement and initial joint customer with DMG MORI as the preferred melt pool monitoring system for their LASERTEC SLM machines.
  • Expanded team to support current partnerships. North American team additions:
    • Scott Hill – Director of Sales Western United States – Leveraging over 20 years in the AM industry, Scott is an accomplished sales professional and a respected industry veteran with experience building strategic relationships and selling 3D hardware and services.
    • Carl Thompson – Director of Sales Eastern United States – With over 13 years of sales management experience in AM, Carl is experienced at working with the Department of Defense and federal contractors.
  • Formed partnership with Northwestern University for the development and expansion of industry leading PrintRite3D In-Process Quality Assurance technology for an application to powder-blow Directed Energy Deposition (DED) additive processes.
  • Partnered with IN4.OS, a leader in advanced manufacturing, to build Smart Factories of the Future to meet the demands of high technology sectors including defense, space, aerospace and life sciences, focusing on ensuring the highest standard of quality during the additive manufacturing process.
  • Awarded contract from Coherent, Inc. (NASDAQ: COHR), one of the world’s leading providers of lasers and laser-based technology for scientific, commercial, and industrial customers, for new PrintRite3D Lite In-Process Quality Assurance System.

Full Year 2020 Operational Highlights

  • Announced several key contract wins to further validate the Company’s technology, including:
    • Contract for an initial system by a leading global energy technology provider, to begin production deployment of PrintRite3D® in-process quality assurance software, following a successful Rapid Test and Evaluation (RTE) program.
    • Extended relationship with Additive Industries, a 3D metal printing equipment manufacturer to OEM its PrintRite3D® Quality Assurance and Monitoring system and the two companies have completed the certification process designating MetalFAB1 printers are now PrintRite3D® Ready.
      • Provides In-Process Melt-Pool Monitoring on Quad Laser Systems.
    • Contract by Mitsubishi Heavy Industries, a global leader in engineering and manufacturing, to implement PrintRite3D® in-process quality assurance (IPQA®) software. The PrintRite3D system will be installed on a laser powder bed fusion system for the development and qualification of MHI additive manufacturing production processes.
    • Contract to implement its PrintRite3D Real-Time Melt Pool Analytics technology at Northwestern University.
    • Contract by the Mississippi State University Center for Advanced Vehicular Systems (CAVS), a world-class interdisciplinary research center that uses state-of-the-art technology to address engineering challenges facing U.S. mobility industries.
  • Launched Printrite3D® Production Series that introduces the ‘Production Dashboard’ and provides production managers with critical metrics, insight and actionable information during the production process.
  • Selected Excel3D Advanced Technologies, a provider of 3D manufacturing software as its preferred value-added reseller for sales of Sigma Labs products in India. This agreement expands Sigma Labs global footprint into the world’s fifth-largest manufacturing economy and in conjunction with the Indian government’s initiative of ‘Make in India’, the nation’s vision is to make the country a global manufacturing hub.
  • Entered into joint sales agreement with Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and of sophisticated 3D printing services, to evolve their previously announced memorandum of understanding (MOU) to cooperate on the integration of the Materialise MCP Controller with Sigma Labs’ PrintRite3D® technology and entered into a binding joint sales agreement to begin beta customer commercialization of the integrated PrintRite3D® and Materialise Control Platform (MCP) product.
  • Appointed Steve Immel, a veteran of the 3D printing industry, to the position of Senior Director Business Development, North America to be responsible for engaging with 3D printer OEMS, additive manufacturers, academic institutions and research organizations to propel Sigma Labs PrintRite3D® in-process quality assurance solutions into production applications.
  • Appointed Mark K. Ruport as President and Chief Executive Officer, from his prior position as Executive Chairman, to further drive formation of strategic relationships, growth and sales strategies as the company commercializes its proprietary PrintRite3D technology. John Rice remains non-executive Chairman of the Board and has entered into a consulting contract with the company.
  • Raised $3.6 million in gross proceeds from both a January 2020 private placement of convertible preferred stock and warrants as well as an April 2020 offering of common stock and warrants. Subsequent warrant exercises contributed an additional $6.0 million in gross proceeds to the Company.
  • Awarded two U.S. patents for its industry-leading technology, PrintRite3D®.

Management Commentary

“Despite the challenges of the global pandemic, 2020 was a gratifying year for Sigma Labs,” said Mark K. Ruport, President and CEO of Sigma Labs. “We were able to achieve almost all of our objectives in a very difficult operating environment. The industries that we focus on were hit hard by COVID-19 and caused almost every opportunity we were pursuing to be delayed, reduced in scope and in a few instances, cancelled. Despite the negative impact on our pipeline, we still doubled revenue, put together a very experienced Additive Manufacturing sales team to support our partners, and greatly improved our balance sheet. For our long-term shareholders and investors, we are proud to contrast the Sigma Labs of yesterday, an R&D focused company, to where we stand today, a full-fledged commercial enterprise aggressively taking our technology to all market segments.

“Today, we are seeing increased activity in a what I believe to be a rejuvenated 3D metal printing market. More importantly, this activity is resulting in several new contracts and first quarter revenue consistent with the revenue we generated from prior initial end user contracts. I am very pleased by the start of 2021, which includes the following contracts quarter to date:

  • The recently announced contract with Lockheed Martin for an initial PrintRite3D system
  • A quad laser PrintRite3D system to be delivered to a large European aerospace company through our OEM agreement with Additive Industries; and
  • An initial contract with Ermaksan, a Turkish 3D metal printer OEM, who is providing PrintRite3D integrated with Materialise’s MCP, to a Turkish customer.

“We are beginning to see the value of our investments in building a multi-tiered, leveraged distribution model. It is heartening to see that all three of our most recent strategic relationships have been instrumental in the first three contract months of 2021. Both Additive Industries and Ermaksan will be doing a factory installation of PrintRite3D to be delivered with their printers. It is in anticipation of increased sales activity through these partnerships, that we have increased our headcount by approximately 50% in the last several months, adding field sales teams to work with and facilitate partner sales opportunities and engineering resources to ensure that we can meet the anticipated demand,” explained Ruport.

“Looking ahead into 2021, we are expanding our focus on new markets and opportunities, including aerospace, space exploration and defense. Our strategic alliance with IN4.OS also supports this mission as well, building Smart Factories of the Future to meet the demands of high technology sectors.

“Anticipated upcoming milestones that we hope to achieve include leveraging our sales team to expand sales through our current partnerships, and through direct sales to global end-user manufacturers, universities and R&D organizations. We will continue to seek out new and expanded strategic partnerships with 3D printer OEMs, software companies, and integrators.

“The following are the milestones that you should measure our progress against in the coming year:

  • PrintRite3D Version 7.0, scheduled for this Spring, will continue to demonstrate our ability to innovate and lead the industry when it comes to 3rd Party, agnostic, In-Process Quality Assurance solutions.
  • Expanded sales of PrintRite3D® through our partnerships with DMG MORI and Additive Industries.
  • Increased direct sales of PrintRite3D to global end-user manufacturers, universities and R&D organizations.
  • New and expanded strategic partnerships with 3D printer OEMs, software companies, and integrators.
  • Continued collaboration with international standards organizations to ensure alignment.
  • Further protection of our intellectual property through continued execution of our comprehensive patent strategy; and
  • Initial PrintRite3D® Lite and PrintrRte3D® DED product revenue.

“This is an exciting time for the Additive Manufacturing industry and Sigma Labs. I believe we are better positioned to create sustainable value for our shareholders than at any prior time in the Company’s history,” concluded Ruport.

Fourth Quarter and Full Year 2020 Financial Results

Revenue for the full year of 2020 totaled $807,500 of which $169,500, or 21% was earned in the fourth quarter. This compares to revenues of $402,500 for the full year of 2019, of which $133,000 was earned in the fourth quarter.

Gross profit for the full year of 2020 $215,000, of which the fourth quarter contributed a negative $22,000, compared to gross profit for the full year of 2019 of negative $172,000, of which the fourth quarter contributed negative $105,000.

Total operating expenses for 2020 were $5.9 million, of which $1.5 million were incurred in the fourth quarter. Total operating expenses for 2019 totaled $6.2 million.

Cash used in operating activities for the full year ended December 31, 2020 totaled $4.8 million, compared to $5.5 million in the full year ended December 31, 2019. Cash used in operating activities totaled $1.1 million for the fourth quarter of 2020, as compared to $1.0 million in the fourth quarter of 2019.

Net loss applicable to common shareholders for the full year of 2020 was $7.0 million, or $(1.83) per share, as compared to a net loss applicable to common shareholders of $6.3 million, or $(5.37) per share, in 2019. Net loss in the fourth quarter of 2020 totaled $1.6 million, compared to a net loss of $1.6 million, in the fourth quarter of 2019.

Cash totaled $3.7 million at December 31, 2020, as compared to $0.1 million at December 31, 2019. Subsequent to the close of the fourth quarter, the Company completed a public offering of shares of common stock with gross proceeds of approximately $5.1 million. In addition, warrant exercises during the first quarter of 2021 have contributed an additional $1.1 million in cash proceeds.

Fourth Quarter and Full Year 2020 Results Conference Call

Sigma Labs President and CEO Mark Ruport and CFO Frank Orzechowski will host the conference call, followed by a question and answer period.

To access the call, please use the following information:

Date: Wednesday, March 24, 2021
Time: 4:30 p.m. Eastern time, 1:30 p.m. Pacific time
Toll-free dial-in number: 1-877-407-9039
International dial-in number: 1-201-689-8470
Conference ID: 13717059

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=143795 and via the investor relations section of the Company’s website at www.sigmalabsinc.com.

A replay of the conference call will be available after 7:30 p.m. Eastern time through April 7, 2021.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 13717059

About Sigma Labs

Sigma Labs Inc. is a leading provider of in-process quality assurance (IPQA®) software to the additive manufacturing industry. Sigma Labs specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D® for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process, enabling significant cost-savings and production efficiencies. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things, market and other conditions, Sigma Labs’ business and financial condition, Sigma Labs’ ability to satisfy its capital needs through increasing its revenue and obtaining additional financing, and the impact of COVID-19, general economic, industry or political conditions in the United States or internationally. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see disclosures contained in Sigma Labs’ public filings with the SEC, including the “Risk Factors” in Sigma Labs’ Annual Report on Form 10-K, and which may be viewed at www.sec.gov.

Investor Contact:

Chris Tyson
Executive Vice President
MZ Group – MZ North America
949-491-8235
SGLB@mzgroup.us
www.mzgroup.us

Company Contact:
Steven Gersten
Sigma Internal IR
813-334-9745
investors@sigmalabsinc.com

Sigma Labs, Inc.
Condensed Balance Sheets
(Unaudited)

December 31,
2020
December 31,
2019
ASSETS
Current Assets:
Cash
$ 3,700,814 $ 86,919
Accounts Receivable, net
331,562 55,540
Inventory
659,651 598,718
Prepaid Assets
90,735 199,727
Total Current Assets
4,782,762 940,904
Other Assets:
Property and Equipment, net
138,626 128,723
Intangible Assets, net
753,122 569,341
Investment in Joint Venture
500
Long-Term Prepaid Asset
26,000 52,000
Total Other Assets
917,748 750,564
TOTAL ASSETS
$ 5,700,510 $ 1,691,468
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable
$ 128,937 $ 727,114
Note Payable
50,000
Deferred Revenue
77,957 139,447
Accrued Expenses
243,815 122,658
Total Current Liabilities
450,709 1,039,219
Long-Term Liabilities
Stock Appreciation Rights
48,341
CARES Act Deferred Payroll Taxes
37,728
Total Long-Term Liabilities
86,069
TOTAL LIABILITIES
536,778 1,039,219
Stockholders’ Equity
Preferred Stock, $0.001 par; 10,000,000 shares authorized; 715 and 0 issued and outstanding, respectively
1
Common Stock, $0.001 par; 12,000,000 authorized; 5,995,320 and 1,403,759 issued and outstanding, respectively
5,995 1,404
Additional Paid-In Capital
38,262,744 26,746,439
Accumulated Deficit
(33,105,008) (26,095,594)
Total Stockholders’ Equity
5,163,732 652,249
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$ 5,700,510 $ 1,691,468

Sigma Labs, Inc.
Condensed Statements of Operations
(Unaudited)

Years Ended
December 31, 2020 December 31, 2019
REVENUES
$ 807,488 $ 402,446
COST OF REVENUE
591,957 574,301
GROSS PROFIT (LOSS)
215,531 (171,855)
EXPENSES:
Salaries & Benefits
2,622,162 2,354,329
Stock-Based Compensation
596,842 497,240
Operating R&D Costs
351,404 647,994
Investor & Public Relations
434,852 417,750
Organizational Costs
425,847 530,958
Legal & Professional Service Fees
676,142 664,403
Office Expenses
416,580 747,881
Depreciation & Amortization
105,175 192,569
Other Operating Expenses
285,295 158,706
Total Operating Expenses
5,914,299 6,211,830
LOSS FROM OPERATIONS
(5,698,768) (6,383,685)
OTHER INCOME (EXPENSE)
Interest Income
1,058 18,760
State Incentives
151,657 51,877
Bad Debt Expense
(2,500)
Exchange Rate Gain (Loss)
(1,677) (4,879)
Other Income
361,700 8,263
Interest Expense
(13,908) (8,685)
Loss on Dissolution of Joint Venture
(201)
Total Other Income (Expense)
498,629 62,836
LOSS BEFORE PROVISION FOR INCOME TAXES
(5,200,139) (6,320,849)
Provision for Income Taxes
Net Loss
$ (5,200,139) $ (6,320,849)
Preferred Dividends
1,809,275
Net Loss applicable to Common Stockholders
$ (7,009,414) $ (6,320,849)
Net Loss per Common Share – Basic and Diluted
$ (1.83) $ (5.37)
Weighted Average Number of Shares Outstanding – Basic and Diluted
3,829,716 1,176,278

Sigma Labs, Inc.
Condensed Statements of Cash Flows
(Unaudited)

Years Ended
December 31, 2020 December 31, 2019
OPERATING ACTIVITIES
Net Loss
$ (5,200,139) $ (6,320,849)
Adjustments to reconcile Net Loss to Net Cash used in operating activities:
Noncash Expenses:
Depreciation and Amortization
105,175 192,569
Stock Based Compensation – Employees
596,842 497,240
Stock Based Compensation – Third Party Services
102,775 32,679
Stock Based Compensation – Directors
239,883 300,000
Change in assets and liabilities:
Accounts Receivable
(276,022) (16,740)
Inventory
(60,932) (358,632)
Prepaid Assets
134,991 (184,472)
Accounts Payable
(598,177) 509,626
Deferred Revenue
(61,490) 87,949
Accrued Expenses
121,157 (254,175)
Long-term portion of Stock Appreciation Rights
48,341
Long Term portion of Deferred Payroll Taxes under the CARES Act
37,728
NET CASH USED IN OPERATING ACTIVITIES
(4,809,868) (5,514,805)
INVESTING ACTIVITIES
Purchase of Property and Equipment
(88,074) (33,487)
Purchase of Intangible Assets
(210,785) (174,224)
Payment Received from Notes Receivable
121,913
Dissolution of Joint Venture
500
NET CASH USED IN INVESTING ACTIVITIES
(298,359) (85,798)
FINANCING ACTIVITIES
Gross Proceeds from Public and Private Issuances of Securities
3,600,000 4,981,221
Less Offering Costs
(820,228) (649,329)
Payment of Note Payable
(50,000)
Proceeds from Exercise of Warrants
5,992,350 75,848
NET CASH PROVIDED BY FINANCING ACTIVITIES
8,722,122 4,407,740
NET CHANGE IN CASH FOR PERIOD
3,613,895 (1,192,863)
CASH AT BEGINNING OF PERIOD
86,919 1,279,782
CASH AT END OF PERIOD
$ 3,700,814 $ 86,919
Supplemental Disclosures:
Noncash investing and financing activities disclosure:
Issuance of Common Shares for Preferred Dividends
$ 1,809,275 $
Disclosure of Cash Received for:
Issuance of Preferred Stock for Exercise of Preferred Warrants
$ 5,992,350 $
Other noncash operating activities disclosure:
Issuance of Securities for services
$ 342,657 $ 335,679
Disclosure of cash paid for:
Interest
$ 13,908 $ 5,069
Income Taxes
$ $

SOURCE: Sigma Labs, Inc.

Wednesday, March 24th, 2021 Uncategorized Comments Off on $SGLB Reports Fourth Quarter and Full Year 2020 Financial Results

$GNPX to Present at Spring 2021 Oncology Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 – April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual company overview that includes GNPX’s novel gene therapies for non-small cell lung cancer and diabetes. Varner’s presentation is scheduled to begin at 2 p.m. Eastern Time on Monday, March 29, and he will be available for one-on-one meetings with investors throughout the conference. Genprex invites investors to register at https://ibn.fm/0Y1gF and join the webcast presentation.

To view the full press release, visit: https://ibn.fm/ETMhJ

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, March 24th, 2021 Uncategorized Comments Off on $GNPX to Present at Spring 2021 Oncology Investor Conference

$AMST Establishes New Paradigm in Surging E-Learning Space

NEW YORK, March 24, 2021  — via InvestorWire — Amesite Inc. (NASDAQ: AMST) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, “The Move to e-Learning Is Heating Up,” please visit: https://nnw.fm/aQlsU

To deliver e-learning that works, tech platforms must address and meet the widely disparate needs of individual schools and varied businesses. A one-size-fits-all approach is doomed to fail when trying to educate, especially in a virtual venue. There’s a critical need for tailored programs as well as wholesale improvement in the way content is created and delivered.

Technology innovator Amesite Inc. (NASDAQ: AMST) has established a new paradigm in e-learning. The company has created what is arguably the most advanced artificial intelligence driven online learning platform in the entire industry. With the capacity to upload an organization’s entire training and educational materials into a single point of access, Amesite’s customizable SaaS (software-as-a-service) platform is engaging, easy to use and delivers concrete measurable results. The company’s cloud-based platform and content creation services uniquely provide fully managed learning environments that easily integrate and work for business, universities, and K-12 schools.

About Amesite Inc.

Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. Amesite-offered courses and programs are branded to our customers. For more information, visit www.Amesite.com .

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://nnw.fm/AM .

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).

For more information please visit https://www.NetworkNewsWire.com .

Please see full terms of use and disclaimers on the NetworkNewsWire website, applicable to all content provided by NNW wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Wednesday, March 24th, 2021 Uncategorized Comments Off on $AMST Establishes New Paradigm in Surging E-Learning Space

$ATNF CEO Releases Stockholder Letter

180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in November 2020. The letter noted the company’s achievement in both legacy-related issues and strengthening its balance sheet. A highlight mentioned in the letter was that the company had reduced its debt from $5 million to $316,000. Woody also reported that the company had converted $3 million in preferred equity to equity. In the letter, Woody also noted that the company had added two new members to its board of directors and was in the process of adding two additional independent directors to its board, which would bring ATNF in compliance with NASDAQ’s continued listing requirements. The letter also highlighted 180 Life Sciences exciting pipeline, including its three clinical programs: Early Dupuytren’s contracture, a fibrotic disease of the hand; frozen shoulder; and post-operative cognitive delirium disorder and dysfunction, a major unmet clinical need occurring in the elderly patient population. “At 180 Life Sciences, we continue to move forward on all fronts. Including efforts to increase visibility for our team and its mission. We are proactively working on telling our story through a steady flow of participation in investor conferences, thought leadership opportunities through earned media, and continued amplification through social media channels,” wrote ATNF CEO James Woody in the letter. “It is important to note that our business model itself is unique for a biotech company. Almost all our clinical studies to date have been funded in full through grants. While ultimately, we intend to fund some studies internally, we anticipate our operating expenses will remain low relative to our peers. There are many advantages of doing clinical development mostly with academic leaders, both in cost, efficiency and credibility.”

To view the full press release, visit http://ibn.fm/upPT4

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, March 24th, 2021 Uncategorized Comments Off on $ATNF CEO Releases Stockholder Letter

$XPHYF Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, as well as focusing on other potential pandemic biosensor tech efforts to combat the spread of the swine flu (‘H1N1′) and avian flu (‘H5N1’) viruses. The company states it is planning to launch its first biosensor product commercially during the latter half of 2021. The biosensor tests will be additions to XPhyto’s portfolio.”

To view the full article, visit: https://ibn.fm/oC9EC

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, March 24th, 2021 Uncategorized Comments Off on $XPHYF Working to Expand Test Portfolio

$PLTXF Partners with Well-Known Chef, Launches PlantXReset Program

PlantX Life (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has announced a collaboration with chef Anne Thornton, a classically trained chef, culinary sustainability expert, writer, TV personality and former host of Food Network’s “Dessert First.” According to the announcement, Thornton, who is known for her signature nutritious and versatile recipes, will create exclusive meals for the company’s new PlantXReset program. The program is inspired by Thornton’s famous Plant Reset program, which is a five-day, plant-powered, sustainable-living meal initiative. The PlantXReset meals will initially be available in Canada, but the company anticipates the meals will be offered in the United States through e-commerce platforms. PlantX partnered with Thornton because of her passion for health and wellness and her love for the planet. The exclusive meals offered through the PlantXReset program will feature nutrient-dense, superfood-laden, adaptogen-laced, gluten-free, refined-sugar-free, dairy-free, soy-free, corn-free, low-fat meals. “Anne is a legend in the culinary industry, and we are so excited to start our collaboration with her,” said PlantX founder Sean Dollinger in the press release. “Her incredible expertise and dedication to human and planetary health are fully aligned with PlantX’s values, and together we hope to help our plant-based community thrive and reach new levels of health and wellness.”

To view the full press release, visit https://ibn.fm/3RZ4I

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier and happier life. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, March 24th, 2021 Uncategorized Comments Off on $PLTXF Partners with Well-Known Chef, Launches PlantXReset Program